Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the stock.

A number of other research analysts also recently issued reports on the stock. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Northland Securities restated a “market perform” rating and issued a $2.00 target price on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Oncternal Therapeutics Stock Performance

Shares of ONCT stock opened at $0.53 on Friday. Oncternal Therapeutics has a 1-year low of $0.53 and a 1-year high of $13.14. The stock has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18. The stock has a 50-day moving average of $1.06 and a 200-day moving average of $3.72.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.